F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors
Condition: Solid Tumors
Sponsor: Fore Biotherapeutics
F8394-201a: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
Oral BRAF inhibitor FORE8394 in combination with cobicistat
For patients with an advanced or metastatic BRAF fusion positive solid tumor (excluding colorectal cancer or pancreatic ductal adenocarcinoma) that has progressed on all available standard of care treatment. Patients cannot have been treated with any BRAF or pan-RAF inhibitor.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.